1. Molecular reframing of fibroblasts during resolution of arthritis
- Author
-
Andreas Ramming, Simon Rauber, Hashem Mohammadian, Christian Schmidkonz, Armin Atzinger, Alina Soare, Christoph Treutlein, Samuel Kemble, Christopher Mahony, Manuel Geisthoff, Mario Angeli, Maria Raimondo, Cong Xu, Kai-Ting Yang, Le Lu, Hannah Labinsky, Mina Saad, Charles Gwellem, Eleni Kampylafka, Johannes Knitza, Jörg Distler, Megan Hanlon, Ursula Fearon, Douglas Veale, Frank Roemer, Tobias Bäuerle, Hans Maric, Simone Maschauer, Christopher Buckley, Adam Croft, Torsten Kuwert, Olaf Prante, Juan Cañete, and Georg Schett
- Abstract
Fibroblasts are key orchestrators of inflammation. Little is known whether these cells change phenotype during resolution of inflammation. We adopted a method to visualise fibroblast activation during inflammation in humans in vivo, which is based on a fibroblast activation protein (FAP) tracer detected by positron emission tomography (PET). While tracer accumulation was high in active arthritis, it decreased significantly after TNF- and IL-17A inhibition. Biopsy-based scRNA-seq analyses in experimental arthritis demonstrated that FAP signal reduction reflected a phenotypic switch from pro-inflammatory MMP3+/IL6+ fibroblasts (high FAP internalisation) to pro-resolving CD200+DKK3+ fibroblasts (low FAP internalisation). Spatial transcriptomics of human joints revealed that pro-resolving niches of CD200+DKK3+ fibroblasts clustered with innate lymphoid cells (ILC)2, whereas MMP3+/IL6+ fibroblasts were co-localised with inflammatory immune cells. CD200+DKK3+ fibroblasts stabilised the ILC2 phenotype and induced resolution of arthritis via CD200/CD200R1 pathway. Taken together, these data suggest a dynamic molecular regulation of the mesenchymal compartment during resolution of inflammation.
- Published
- 2023
- Full Text
- View/download PDF